



New Study Demonstrates the Superiority of Crosslinked Hyaluronic Acid in Improving the Skin Barrier Function

Irvine, Calif., April 4, 2016 – A new study* published in the Journal of Drugs in Dermatology titled “Pilot Comparative Study of the Topical Action of a Novel, Crosslinked Resilient Hyaluronic Acid on Skin Hydration and Barrier Function in a Dynamic, Three-Dimensional Human Explant Model” demonstrates that topically-applied crosslinked resilient Hyaluronic Acid (RHA™) is superior to non-crosslinked (linear) low and high molecular weight hyaluronic acid in increasing water content of the skin, maintaining skin integrity and improving skin barrier function.

Hyaluronic acid (HA) is a naturally-occurring molecule that helps maintain skin structure and is a popular ingredient in many topical cosmetic formulations. To date, few formulations have included crosslinked HA, which helps consumers maintain the youthful appearance of their skin.

“This is an exciting study, featuring state-of-the-art analytical techniques. It’s the first study to reveal important differences between specific types of HA, and points to a key role for topical RHA in skin rehydration and rejuvenation,” says lead study author Dr. Hema Sundaram. Dr. Sundaram is a Washington, DC area dermatologist who collaborated on the publication with Swiss-based TEOXANE Laboratories**. “RHA was originally developed by TEOXANE as the primary component of their injectable dermal fillers line, indicated for the aesthetic treatment of skin wrinkles and facial contours. Its proprietary crosslinking confers longevity and enhances mechanical characteristics. Our latest research shows that crosslinking may also be beneficial in a topical HA formulation. If we effectively address the skin’s fundamental hydration needs, it may tolerate and respond better to other topical treatments and cosmetic procedures.”

The study was conducted to evaluate the effects of crosslinked RHA vs. linear, non-crosslinked low molecular weight (LMW) HA and high molecular weight (HMW) HA using human skin explant surfaces. In the study, researchers found that RHA was a more efficacious humectant than LMW HA and a more efficacious occlusive moisturizer than HMW HA. Furthermore, topical crosslinked RHA significantly improved the skin barrier structure and function by helping to better retain moisture in the skin.

“When we launched the TEOXANE skin care line in the U.S. in early 2014, we were aware of the great properties of RHA and these findings further confirm the hydration benefits of crosslinked HA,” said Chris Marmo, President of Beauty at ALPHAЕON. “Currently we offer over 10 different products with RHA Resilient Hyaluronic Acid®, all of them specifically designed to address the needs of consumers who are seeking the best options in aesthetic facial skin care. This study underscores our commitment to delivering the best aesthetic products and is a true example of the intersection of technology innovation and improved consumer results we are striving to achieve.”

ALPHAЕON recommends speaking to a board-certified dermatologist or plastic surgeon about the TEOXANE line of products. To find a physician please visit www.alphaeon.com.

About ALPHAEON Corporation

ALPHAEON Corporation is a social commerce company with the goal of transforming self-pay healthcare by bringing to market highly innovative products and services to promote consumer wellness, beauty and performance. The company works in partnership with board certified physicians ensuring access to leading advancements in lifestyle healthcare. For more information, please visit www.alphaeon.com.

*The full study is available in Volume 15, Issue 4 of the Journal of Drugs in Dermatology, published April 2016.

**Dr. Sundaram is also an equity holder in ALPHAEON Corporation and Strathspey Crown Holdings, LLC, the parent company of ALPHAEON.

ALPHAEON PRESS CONTACTS:

Jenna Mons, Senior Vice President of Marketing and Communications

Tel: +1-904-343-3449

Email: press@alphaeon.com

Ashwin Agarwal, Vice President of Investor Relations and Finance

Tel: +1-949-284-4730

Email: IR@alphaeon.com

###